Pub Date : 2026-01-01Epub Date: 2025-12-02DOI: 10.1080/00365521.2025.2594789
Feng Chen, Zhenhua Zhou, Liu Zhuang, Rongrong Zou, Yingfei Wen, Xinyi Deng
Objectives: The clinical significance of HBeAg/HBeAb coexistence in pediatric chronic hepatitis B (CHB) remains unclear. This study assessed antiviral efficacy and predictors of functional cure in HBeAg/HBeAb-positive children/adolescents treated with PEG-IFNα-2a or entecavir (ETV).
Methods: We retrospectively analyzed 54 CHB patients (<18 years) treated from 2016-2022, stratified by treatment (PEG-IFNα-2a vs. ETV), age (≤7 vs. >7 years), and 48-week HBsAg seroconversion status. Biochemical and virological responses were assessed at 4, 12, 24 and 48 weeks. Cumulative incidence was calculated via Kaplan-Meier analysis, and predictive performance was evaluated using ROC curves and DeLong tests.
Results: ETV demonstrated superior ALT (24 weeks: 54.2% vs 16.0%, X2=7.873, p = 0.005; 48 weeks: 64.0% vs 20.8%, X2=9.317, p = 0.002) and AST normalization rate (24 weeks: 45.8% vs 16.0%, X2=5.131, p = 0.024; 48 weeks: 64.0% vs 12.5%, X2=13.680, p < 0.001), and faster HBV DNA decline (4 weeks: 5.16 vs 6.72 log10IU/mL, Z=-2.843, p = 0.004; 12 weeks: 3.00 vs 5.06 log10IU/mL, Z=-1.895, p = 0.058) than PEG-IFNα-2a. However, PEG-IFNα-2a achieved greater HBsAg reduction (late phase, all p < 0.01) and higher HBsAg serological response (48 weeks: 36.0% vs 12.0%, X2=3.947, p = 0.047) and seroconversion (48 weeks: 28.0% vs 12.0%, X2=2.000, p = 0.157). Younger patients (≤7 years) had higher HBsAg seroconversion rates (48 weeks: 28.1% vs 5.6%, X2=3.668, p = 0.055). Early qHBsAg levels (weeks 12/24) strongly predicted functional cure (AUC > 0.90).
Conclusions: ETV was more effective for short-term viral suppression and hepatic inflammation reduction, while PEG-IFNα-2a promoted HBsAg decline and functional cure. Younger age and early qHBsAg levels were key predictors of treatment success.
目的:HBeAg/HBeAb共存在儿童慢性乙型肝炎(CHB)中的临床意义尚不清楚。本研究评估了HBeAg/ hbeab阳性儿童/青少年接受PEG-IFNα-2a或恩替卡韦(ETV)治疗的抗病毒疗效和功能治愈的预测因素。方法:回顾性分析54例慢性乙型肝炎患者(7年)和48周HBsAg血清转化情况。在4、12、24和48周时评估生化和病毒学反应。通过Kaplan-Meier分析计算累积发病率,采用ROC曲线和DeLong检验评估预测性能。结果:ETV的ALT(24周:54.2% vs 16.0%, X2=7.873, p = 0.005; 48周:64.0% vs 20.8%, X2=9.317, p = 0.002)和AST正常化率(24周:45.8% vs 16.0%, X2=5.131, p = 0.024; 48周:64.0% vs 12.5%, X2=13.680, p 10IU/mL, Z=-2.843, p = 0.004; 12周:3.00 vs 5.06 log10IU/mL, Z=-1.895, p = 0.058)均优于PEG-IFNα-2a。然而,PEG-IFNα-2a取得了更大的HBsAg降低(晚期,均p 2=3.947, p = 0.047)和血清转化(48周:28.0% vs 12.0%, X2=2.000, p = 0.157)。年龄较小的患者(≤7岁)HBsAg血清转换率较高(48周:28.1% vs 5.6%, X2=3.668, p = 0.055)。早期qHBsAg水平(第12/24周)强烈预测功能性治愈(AUC > 0.90)。结论:ETV在短期抑制病毒和减轻肝脏炎症方面更有效,而PEG-IFNα-2a促进HBsAg下降和功能治愈。较年轻和早期qHBsAg水平是治疗成功的关键预测因素。
{"title":"Clinical treatment outcomes of chronic hepatitis B pediatric with coexistence of HBeAg and HBeAb.","authors":"Feng Chen, Zhenhua Zhou, Liu Zhuang, Rongrong Zou, Yingfei Wen, Xinyi Deng","doi":"10.1080/00365521.2025.2594789","DOIUrl":"10.1080/00365521.2025.2594789","url":null,"abstract":"<p><strong>Objectives: </strong>The clinical significance of HBeAg/HBeAb coexistence in pediatric chronic hepatitis B (CHB) remains unclear. This study assessed antiviral efficacy and predictors of functional cure in HBeAg/HBeAb-positive children/adolescents treated with PEG-IFNα-2a or entecavir (ETV).</p><p><strong>Methods: </strong>We retrospectively analyzed 54 CHB patients (<18 years) treated from 2016-2022, stratified by treatment (PEG-IFNα-2a vs. ETV), age (≤7 vs. >7 years), and 48-week HBsAg seroconversion status. Biochemical and virological responses were assessed at 4, 12, 24 and 48 weeks. Cumulative incidence was calculated <i>via</i> Kaplan-Meier analysis, and predictive performance was evaluated using ROC curves and DeLong tests.</p><p><strong>Results: </strong>ETV demonstrated superior ALT (24 weeks: 54.2% vs 16.0%, X<sup>2</sup>=7.873, <i>p</i> = 0.005; 48 weeks: 64.0% vs 20.8%, X<sup>2</sup>=9.317, <i>p</i> = 0.002) and AST normalization rate (24 weeks: 45.8% vs 16.0%, X<sup>2</sup>=5.131, <i>p</i> = 0.024; 48 weeks: 64.0% vs 12.5%, X<sup>2</sup>=13.680, <i>p</i> < 0.001), and faster HBV DNA decline (4 weeks: 5.16 vs 6.72 log<sub>10</sub>IU/mL, Z=-2.843, <i>p</i> = 0.004; 12 weeks: 3.00 vs 5.06 log<sub>10</sub>IU/mL, Z=-1.895, <i>p</i> = 0.058) than PEG-IFNα-2a. However, PEG-IFNα-2a achieved greater HBsAg reduction (late phase, all <i>p</i> < 0.01) and higher HBsAg serological response (48 weeks: 36.0% vs 12.0%, X<sup>2</sup>=3.947, <i>p</i> = 0.047) and seroconversion (48 weeks: 28.0% vs 12.0%, X<sup>2</sup>=2.000, <i>p</i> = 0.157). Younger patients (≤7 years) had higher HBsAg seroconversion rates (48 weeks: 28.1% vs 5.6%, X<sup>2</sup>=3.668, <i>p</i> = 0.055). Early qHBsAg levels (weeks 12/24) strongly predicted functional cure (AUC > 0.90).</p><p><strong>Conclusions: </strong>ETV was more effective for short-term viral suppression and hepatic inflammation reduction, while PEG-IFNα-2a promoted HBsAg decline and functional cure. Younger age and early qHBsAg levels were key predictors of treatment success.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"114-123"},"PeriodicalIF":1.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145661858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-14DOI: 10.1080/00365521.2025.2585113
Gyda G Christiansen, Ingvild Farnes, Marianne J Hjermstad, Knut Jørgen Labori
Background: Borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC) constitute a heterogeneous disease spectrum with variable tumour biology and treatment responses, making clinical decision-making challenging. Improved prognostic markers are needed to guide individualised treatment strategies. This study aims to determine whether quality of life (QoL) at the time of diagnosis is associated with survival in patients diagnosed with BRPC and LAPC.
Methods: Between 2018 and 2020, a total of 230 consecutive patients with BRPC and LAPC were included in a population-based study. Patients completed the EORTC QLQ-C30 questionnaire at the time of diagnosis. Clinical data were collected prospectively. The association between QoL and survival was assessed using Cox regression models.
Results: Baseline QoL data were available for 143 (62%) patients. Median overall survival from time of diagnosis was 14 (95% CI 11.1-16.9) months. Multivariate analyses showed that emotional functioning, financial impact and constipation were significantly associated with survival. Constipation was the strongest prognostic factor (HR 1.95, 95% CI 1.28-2.96, p < 0.001). Patients with a high constipation score had a median overall survival of 10 months (95% CI, 7.2-12.8) compared to 16 months (95% CI, 11.9-20.0) for those with a low score (p = 0.009).
Conclusions: In patients with BRPC and LAPC, several baseline QoL domains, especially constipation, are significant prognostic indicators. Routine QoL assessment may facilitate personalised, patient-centred care that improves both clinical outcomes and QoL during treatment.
背景:边缘可切除(BRPC)和局部晚期胰腺癌(LAPC)构成了一种异质性疾病谱系,具有不同的肿瘤生物学和治疗反应,使临床决策具有挑战性。需要改善预后指标来指导个体化治疗策略。本研究旨在确定诊断为BRPC和LAPC的患者在诊断时的生活质量(QoL)是否与生存相关。方法:在2018年至2020年期间,共有230例BRPC和LAPC患者被纳入一项基于人群的研究。患者在诊断时完成EORTC QLQ-C30问卷。前瞻性收集临床资料。使用Cox回归模型评估生活质量与生存之间的关系。结果:143例(62%)患者可获得基线生活质量数据。诊断后的中位总生存期为14个月(95% CI 11.1-16.9)。多变量分析显示,情绪功能、经济影响和便秘与生存率显著相关。便秘是最强的预后因素(HR 1.95, 95% CI 1.28-2.96, p p = 0.009)。结论:在BRPC和LAPC患者中,几个基线生活质量域,特别是便秘,是重要的预后指标。常规的生活质量评估可以促进个性化的、以患者为中心的护理,从而改善临床结果和治疗期间的生活质量。
{"title":"Association between baseline quality of life and survival in patients with non-metastatic, advanced pancreatic cancer.","authors":"Gyda G Christiansen, Ingvild Farnes, Marianne J Hjermstad, Knut Jørgen Labori","doi":"10.1080/00365521.2025.2585113","DOIUrl":"10.1080/00365521.2025.2585113","url":null,"abstract":"<p><strong>Background: </strong>Borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC) constitute a heterogeneous disease spectrum with variable tumour biology and treatment responses, making clinical decision-making challenging. Improved prognostic markers are needed to guide individualised treatment strategies. This study aims to determine whether quality of life (QoL) at the time of diagnosis is associated with survival in patients diagnosed with BRPC and LAPC.</p><p><strong>Methods: </strong>Between 2018 and 2020, a total of 230 consecutive patients with BRPC and LAPC were included in a population-based study. Patients completed the EORTC QLQ-C30 questionnaire at the time of diagnosis. Clinical data were collected prospectively. The association between QoL and survival was assessed using Cox regression models.</p><p><strong>Results: </strong>Baseline QoL data were available for 143 (62%) patients. Median overall survival from time of diagnosis was 14 (95% CI 11.1-16.9) months. Multivariate analyses showed that emotional functioning, financial impact and constipation were significantly associated with survival. Constipation was the strongest prognostic factor (HR 1.95, 95% CI 1.28-2.96, <i>p</i> < 0.001). Patients with a high constipation score had a median overall survival of 10 months (95% CI, 7.2-12.8) compared to 16 months (95% CI, 11.9-20.0) for those with a low score (<i>p</i> = 0.009).</p><p><strong>Conclusions: </strong>In patients with BRPC and LAPC, several baseline QoL domains, especially constipation, are significant prognostic indicators. Routine QoL assessment may facilitate personalised, patient-centred care that improves both clinical outcomes and QoL during treatment.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"53-60"},"PeriodicalIF":1.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-18DOI: 10.1080/00365521.2025.2588226
Marion Delplanque, Véronique Hentgen, Sophie Georgin-Lavialle
{"title":"Article commentary on \"long-term use of colchicine is associated with incident cirrhosis: a real-world cohort study\" by naffaa.","authors":"Marion Delplanque, Véronique Hentgen, Sophie Georgin-Lavialle","doi":"10.1080/00365521.2025.2588226","DOIUrl":"10.1080/00365521.2025.2588226","url":null,"abstract":"","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"111-113"},"PeriodicalIF":1.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145550348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-04DOI: 10.1080/00365521.2025.2597266
Raffaele Li Voti, Fabio Salvatore Macaluso, Sara Renna, Angelo Casà, Alessandro Termini, Emanuele Orlando, Ivan Fricano, Josephine Vastarella, Ambrogio Orlando
Background: Post-colectomy enteritis is a rare but potentially life-threatening complication of colectomy in patients with ulcerative colitis. The current evidence is limited to case reports and small retrospective case series, suggesting that this condition is likely underdiagnosed and often recognized only in advanced stages.
Objective: We performed a comprehensive bibliographic search in Medline (via PubMed) up to April 2025 to collect available data on its clinical presentation, management, and outcome.
Results: Although its pathogenesis remains poorly understood, the disease typically presents with severe diarrhea, abdominal pain, and systemic inflammatory signs requiring prompt intervention. First-line therapy consists of high-dose intravenous corticosteroids, whereas biologic therapy may be needed in refractory or severe cases. Management remains largely empirical, and delayed diagnosis may contribute to increased morbidity and mortality. Implementing a structured diagnostic and therapeutic approach could improve early recognition and treatment, while further studies are required to clarify underlying mechanisms, optimize management strategies, and define the relationship between this condition and other forms of small bowel involvement in ulcerative colitis.
Conclusions: Raising awareness of post-colectomy enteritis among clinicians is crucial to prevent misdiagnosis and to reduce the burden of this rare but severe post-surgical complication.
{"title":"Post-colectomy enteritis with ulcerative colitis: a rare but severe inflammatory condition.","authors":"Raffaele Li Voti, Fabio Salvatore Macaluso, Sara Renna, Angelo Casà, Alessandro Termini, Emanuele Orlando, Ivan Fricano, Josephine Vastarella, Ambrogio Orlando","doi":"10.1080/00365521.2025.2597266","DOIUrl":"10.1080/00365521.2025.2597266","url":null,"abstract":"<p><strong>Background: </strong>Post-colectomy enteritis is a rare but potentially life-threatening complication of colectomy in patients with ulcerative colitis. The current evidence is limited to case reports and small retrospective case series, suggesting that this condition is likely underdiagnosed and often recognized only in advanced stages.</p><p><strong>Objective: </strong>We performed a comprehensive bibliographic search in Medline (<i>via</i> PubMed) up to April 2025 to collect available data on its clinical presentation, management, and outcome.</p><p><strong>Results: </strong>Although its pathogenesis remains poorly understood, the disease typically presents with severe diarrhea, abdominal pain, and systemic inflammatory signs requiring prompt intervention. First-line therapy consists of high-dose intravenous corticosteroids, whereas biologic therapy may be needed in refractory or severe cases. Management remains largely empirical, and delayed diagnosis may contribute to increased morbidity and mortality. Implementing a structured diagnostic and therapeutic approach could improve early recognition and treatment, while further studies are required to clarify underlying mechanisms, optimize management strategies, and define the relationship between this condition and other forms of small bowel involvement in ulcerative colitis.</p><p><strong>Conclusions: </strong>Raising awareness of post-colectomy enteritis among clinicians is crucial to prevent misdiagnosis and to reduce the burden of this rare but severe post-surgical complication.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"104-110"},"PeriodicalIF":1.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145669508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Sarcopenia is an age-related geriatric syndrome. We aimed to investigate the association between sarcopenia and adverse events after endoscopic submucosal dissection (ESD) for gastrointestinal early-stage cancer and precancerous lesions.
Patients and methods: We enrolled 180 patients with gastrointestinal lesions who underwent ESD in the First Hospital of Hebei Medical University between April 2020 and November 2023 and divided them into the sarcopenia group (31 patients) and the non-sarcopenia group (149 patients). Their clinical information, ESD-related postoperative complications were then compared.
Results: The median age was higher (p < 0.05) and body mass index (BMI), albumin (ALB) level, and prognostic nutritional index (PNI) were lower (all p < 0.05) in the sarcopenia group compared to the non-sarcopenia group. The percentage of those with Common Terminology Criteria for Adverse Events (CTCAE) ≥ grade 1 was higher in the sarcopenia group (p < 0.01). Univariate logistic regression analysis showed that ALB, PNI and sarcopenia are risk factors for CTCAE ≥ 1 (both p < 0.05). Multivariate analyses indicated that sarcopenia (OR = 2.961; 95% CI: 1.220-7.188; p < 0.05) was a significant independent risk factor.
Conclusions: Sarcopenia is an independent risk factor for adverse events after ESD for gastrointestinal early cancer and precancerous lesions. Early preoperative identification and improvement of sarcopenic status by clinicians are therefore critical for enhancing ESD safety and optimizing patient recovery trajectories.
肌少症是一种与年龄相关的老年综合征。我们的目的是研究在内镜下粘膜下剥离(ESD)治疗胃肠道早期癌症和癌前病变后肌肉减少症与不良事件之间的关系。患者和方法:选取2020年4月至2023年11月在河北医科大学第一医院行ESD手术的胃肠道病变患者180例,分为肌少症组(31例)和非肌少症组(149例)。比较两组患者的临床资料及术后静电相关并发症。结果:中位年龄增高(p p p p p p)结论:肌少症是胃肠道早期癌及癌前病变ESD后不良事件的独立危险因素。因此,临床医生在术前早期识别和改善肌肉减少状态对于提高ESD安全性和优化患者恢复轨迹至关重要。
{"title":"The effect of sarcopenia on postoperative adverse events after endoscopic submucosal dissection for early gastrointestinal cancer.","authors":"Yueyao Sun, Yanjie Zhang, Bo Tian, Ting Liu, Ni Wang, Shuangshuang Han, Mingda Xuan, Rui Zhang, Kunyi Liu, Shuliang Liu, Yuan Cheng, Jiao Jiao, Weifang Yu","doi":"10.1080/00365521.2025.2594784","DOIUrl":"10.1080/00365521.2025.2594784","url":null,"abstract":"<p><strong>Introduction: </strong>Sarcopenia is an age-related geriatric syndrome. We aimed to investigate the association between sarcopenia and adverse events after endoscopic submucosal dissection (ESD) for gastrointestinal early-stage cancer and precancerous lesions.</p><p><strong>Patients and methods: </strong>We enrolled 180 patients with gastrointestinal lesions who underwent ESD in the First Hospital of Hebei Medical University between April 2020 and November 2023 and divided them into the sarcopenia group (31 patients) and the non-sarcopenia group (149 patients). Their clinical information, ESD-related postoperative complications were then compared.</p><p><strong>Results: </strong>The median age was higher (<i>p</i> < 0.05) and body mass index (BMI), albumin (ALB) level, and prognostic nutritional index (PNI) were lower (all <i>p</i> < 0.05) in the sarcopenia group compared to the non-sarcopenia group. The percentage of those with Common Terminology Criteria for Adverse Events (CTCAE) ≥ grade 1 was higher in the sarcopenia group (<i>p</i> < 0.01). Univariate logistic regression analysis showed that ALB, PNI and sarcopenia are risk factors for CTCAE ≥ 1 (both <i>p</i> < 0.05). Multivariate analyses indicated that sarcopenia (OR = 2.961; 95% CI: 1.220-7.188; <i>p</i> < 0.05) was a significant independent risk factor.</p><p><strong>Conclusions: </strong>Sarcopenia is an independent risk factor for adverse events after ESD for gastrointestinal early cancer and precancerous lesions. Early preoperative identification and improvement of sarcopenic status by clinicians are therefore critical for enhancing ESD safety and optimizing patient recovery trajectories.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"36-43"},"PeriodicalIF":1.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-12DOI: 10.1080/00365521.2025.2588230
Wenjing Sun, Lishi Zhao, Yamei Ran, Wenyan Zhao, Li Zhang, Juan Xiao, Yongmei Peng, Zhongxiao Zhang, Mei Dong, Shu Xiang, Kangqi Wu
Objectives: This study aimed to investigate the efficacy and safety of bowel preparation by linaclotide (Lina) combined with compound polyethylene glycol (PEG) in patients aged over 60 years.
Methods: A multi-center, endoscopist-blind, randomized controlled trial involved 527 patients aged over 60 years scheduled for colonoscopy at two hospitals in Chongqing from January 2022 to December 2023. Participants were randomly assigned to one of three groups: Lina + 2 litres of PEG (L-PEG), 3 L-PEG, or 2 L-PEG. The primary endpoint was the Boston Bowel Preparation Scale (BBPS), with secondary outcomes including the adequate bowel preparation rate (ABPR), adenoma/polyp detection rate (ADR), cecal intubation rate (CIR), cecal intubation time (CIT), willingness to repeat the colonoscopy, bowel preparation costs, and adverse reactions.
Results: The total BBPS scores, ABPR and CIT in the Lina + 2 L-PEG group and the 3 L-PEG group were superior to those in the 2 L-PEG group(p < 0.05). Compared with the 3 L-PEG group, the Lina + 2 L-PEG group and the 2 L-PEG group demonstrated a higher willingness to repeat the colonoscopy, lower costs, and a lower percentage of mild adverse events(p < 0.05). No statistically significant differences were observed among the groups in terms of ADR and CIR.
Conclusions: The bowel preparation efficacy of Lina + 2 L-PEG is comparable to that of 3 L-PEG, yet superior to that of 2 L-PEG. Moreover, Lina + 2 L-PEG is associated with fewer adverse reactions, a lower cost, and a higher willingness to repeat the colonoscopy among patients aged over 60 years.
{"title":"Linaclotide in combination with compound polyethylene glycol powder enhances bowel preparation for colonoscopy in patients aged over 60 years: a multi-center, endoscopist-blind, randomized controlled trial.","authors":"Wenjing Sun, Lishi Zhao, Yamei Ran, Wenyan Zhao, Li Zhang, Juan Xiao, Yongmei Peng, Zhongxiao Zhang, Mei Dong, Shu Xiang, Kangqi Wu","doi":"10.1080/00365521.2025.2588230","DOIUrl":"10.1080/00365521.2025.2588230","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the efficacy and safety of bowel preparation by linaclotide (Lina) combined with compound polyethylene glycol (PEG) in patients aged over 60 years.</p><p><strong>Methods: </strong>A multi-center, endoscopist-blind, randomized controlled trial involved 527 patients aged over 60 years scheduled for colonoscopy at two hospitals in Chongqing from January 2022 to December 2023. Participants were randomly assigned to one of three groups: Lina + 2 litres of PEG (L-PEG), 3 L-PEG, or 2 L-PEG. The primary endpoint was the Boston Bowel Preparation Scale (BBPS), with secondary outcomes including the adequate bowel preparation rate (ABPR), adenoma/polyp detection rate (ADR), cecal intubation rate (CIR), cecal intubation time (CIT), willingness to repeat the colonoscopy, bowel preparation costs, and adverse reactions.</p><p><strong>Results: </strong>The total BBPS scores, ABPR and CIT in the Lina + 2 L-PEG group and the 3 L-PEG group were superior to those in the 2 L-PEG group(<i>p</i> < 0.05). Compared with the 3 L-PEG group, the Lina + 2 L-PEG group and the 2 L-PEG group demonstrated a higher willingness to repeat the colonoscopy, lower costs, and a lower percentage of mild adverse events(<i>p</i> < 0.05). No statistically significant differences were observed among the groups in terms of ADR and CIR.</p><p><strong>Conclusions: </strong>The bowel preparation efficacy of Lina + 2 L-PEG is comparable to that of 3 L-PEG, yet superior to that of 2 L-PEG. Moreover, Lina + 2 L-PEG is associated with fewer adverse reactions, a lower cost, and a higher willingness to repeat the colonoscopy among patients aged over 60 years.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"10-16"},"PeriodicalIF":1.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145496641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-30DOI: 10.1080/00365521.2025.2594779
Joel Kontiainen, Kaisa Lehtomäki, Timo Muhonen, Eetu Heervä, Annika Ålgars, Raija Ristamäki, Hanna Stedt, Annamarja Lamminmäki, Raija Kallio, Tapio Salminen, Teijo Kuopio, Emerik Osterlund, Sonja Aho, Maarit Bärlund, Päivi Halonen, Leena-Maija Soveri, Arno Nordin, Aki Uutela, Bengt Glimelius, Helena Isoniemi, Pia Osterlund
Introduction: Metastatic colorectal cancer (mCRC) represents a growing burden on healthcare, yet comprehensive data on treatment costs across different disease phases remain limited. This study aims to estimate hospital resource utilization and costs of treating mCRC patients according to international up-to-date guidelines.
Materials and methods: The RAXO study aimed at maximising metastasectomy with repeated centralized assessment of resectability (inclusion 2012-2018). Cost data from the six largest Finnish hospital districts (n = 941) in RAXO were collected from mCRC diagnosis to death or the end of 2021. All patient costs were characterized day-by-day to diagnostic, curative, remission, palliative SACT, treatment break, or end-of-life disease phases. The resource utilization and mean costs, in 2021 euros, were calculated per patient per month (PPPM).
Results: The mean PPPM cost for treating mCRC patients was 2323€, when 37% had curative-intent metastasectomy. On average, each month included 0.7 ward days, 1.9 outpatient and 0.1 emergency visits. Outpatient care accounted for 64% of costs, inpatient care for 34%, and emergency room visits for 2%. The higher costs during disease phases involving active tumour-directed treatments (2963€-3059€/PPPM) were balanced by lower costs during remission and treatment break (453€-560€/PPPM). Pharmacy, ward, operating room, and outpatient costs (39%/18%/15%/15%, respectively) were the main drivers for internal hospital billing.
Conclusions: Resource utilization, costs, and cost drivers varied 8-fold between disease phases. Outpatient care accounted for two-thirds, and inpatient care accounted for one-third of costs.
{"title":"Disease-phase-specific resource utilization and healthcare costs in metastatic colorectal cancer: a subgroup analysis of the Finnish RAXO study.","authors":"Joel Kontiainen, Kaisa Lehtomäki, Timo Muhonen, Eetu Heervä, Annika Ålgars, Raija Ristamäki, Hanna Stedt, Annamarja Lamminmäki, Raija Kallio, Tapio Salminen, Teijo Kuopio, Emerik Osterlund, Sonja Aho, Maarit Bärlund, Päivi Halonen, Leena-Maija Soveri, Arno Nordin, Aki Uutela, Bengt Glimelius, Helena Isoniemi, Pia Osterlund","doi":"10.1080/00365521.2025.2594779","DOIUrl":"10.1080/00365521.2025.2594779","url":null,"abstract":"<p><strong>Introduction: </strong>Metastatic colorectal cancer (mCRC) represents a growing burden on healthcare, yet comprehensive data on treatment costs across different disease phases remain limited. This study aims to estimate hospital resource utilization and costs of treating mCRC patients according to international up-to-date guidelines.</p><p><strong>Materials and methods: </strong>The RAXO study aimed at maximising metastasectomy with repeated centralized assessment of resectability (inclusion 2012-2018). Cost data from the six largest Finnish hospital districts (<i>n</i> = 941) in RAXO were collected from mCRC diagnosis to death or the end of 2021. All patient costs were characterized day-by-day to diagnostic, curative, remission, palliative SACT, treatment break, or end-of-life disease phases. The resource utilization and mean costs, in 2021 euros, were calculated per patient per month (PPPM).</p><p><strong>Results: </strong>The mean PPPM cost for treating mCRC patients was 2323€, when 37% had curative-intent metastasectomy. On average, each month included 0.7 ward days, 1.9 outpatient and 0.1 emergency visits. Outpatient care accounted for 64% of costs, inpatient care for 34%, and emergency room visits for 2%. The higher costs during disease phases involving active tumour-directed treatments (2963€-3059€/PPPM) were balanced by lower costs during remission and treatment break (453€-560€/PPPM). Pharmacy, ward, operating room, and outpatient costs (39%/18%/15%/15%, respectively) were the main drivers for internal hospital billing.</p><p><strong>Conclusions: </strong>Resource utilization, costs, and cost drivers varied 8-fold between disease phases. Outpatient care accounted for two-thirds, and inpatient care accounted for one-third of costs.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"61-72"},"PeriodicalIF":1.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-11DOI: 10.1080/00365521.2025.2594782
Halit Kandemir, Güner Kiliç, Ali Karataş, Kenan Moral, Enes Cömert, Beril Demir, Derya Kirman, Murat Kekilli, Mehmet Cindoruk, Tarkan Karakan
Background/objectives: Endoscopic procedures-related musculoskeletal injuries (ERMI) are a major problem in gastroenterologists. ERMI arises from increased workload, extended times of advanced endoscopic procedures, and repetitive overuse. There has been no study for ERMI among gastroenterologist in Türkiye. This study aimed to assess the frequency, causes, and risk factors associated with ERMI among gastroenterologists in Türkiye.
Methods: A 26-item electronic survey was sent to 1,100 Turkish Gastroenterology Association physician members and to 253 gastroenterology fellows still in training. Demographic characteristics, prevalence of ERMI, workload parameters and possible risk factors were evaluated by univariate and multivariate analyses.
Results: The survey was completed by 132 gastroenterologists, 78% of respondent were male, with a mean professional experience of 11 years. Overall, 72% reported experiencing at least one ERMI during their career, and 63.2% reported injuries involving multiple joints. The most commonly affected areas were the neck, left thumb and right wrist. Significant differences in ERMI were observed based on gender, affiliated institution, and total weekly number of procedures. Regarding injury severity, sex and glove size were significant factors. In logistic regression analysis, female sex increased the risk of ERMI by 5.7 times, and performing ERCP procedures increased the risk by 2.4 times.
Conclusions: ERMI is highly prevalent among gastroenterologists in Türkiye and represents a significant occupational health problem with implications on work loss. Preventive strategies such as reducing the volume of procedures, increasing the frequency of breaks, and making ergonomic adjustments in procedure rooms are necessary to reduce the risk of ERMI.
{"title":"A nationwide cross-sectional study on endoscopy-related musculoskeletal injuries: the hidden occupational burden of gastroenterologists in Türkiye.","authors":"Halit Kandemir, Güner Kiliç, Ali Karataş, Kenan Moral, Enes Cömert, Beril Demir, Derya Kirman, Murat Kekilli, Mehmet Cindoruk, Tarkan Karakan","doi":"10.1080/00365521.2025.2594782","DOIUrl":"10.1080/00365521.2025.2594782","url":null,"abstract":"<p><strong>Background/objectives: </strong>Endoscopic procedures-related musculoskeletal injuries (ERMI) are a major problem in gastroenterologists. ERMI arises from increased workload, extended times of advanced endoscopic procedures, and repetitive overuse. There has been no study for ERMI among gastroenterologist in Türkiye. This study aimed to assess the frequency, causes, and risk factors associated with ERMI among gastroenterologists in Türkiye.</p><p><strong>Methods: </strong>A 26-item electronic survey was sent to 1,100 Turkish Gastroenterology Association physician members and to 253 gastroenterology fellows still in training. Demographic characteristics, prevalence of ERMI, workload parameters and possible risk factors were evaluated by univariate and multivariate analyses.</p><p><strong>Results: </strong>The survey was completed by 132 gastroenterologists, 78% of respondent were male, with a mean professional experience of 11 years. Overall, 72% reported experiencing at least one ERMI during their career, and 63.2% reported injuries involving multiple joints. The most commonly affected areas were the neck, left thumb and right wrist. Significant differences in ERMI were observed based on gender, affiliated institution, and total weekly number of procedures. Regarding injury severity, sex and glove size were significant factors. In logistic regression analysis, female sex increased the risk of ERMI by 5.7 times, and performing ERCP procedures increased the risk by 2.4 times.</p><p><strong>Conclusions: </strong>ERMI is highly prevalent among gastroenterologists in Türkiye and represents a significant occupational health problem with implications on work loss. Preventive strategies such as reducing the volume of procedures, increasing the frequency of breaks, and making ergonomic adjustments in procedure rooms are necessary to reduce the risk of ERMI.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"25-35"},"PeriodicalIF":1.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145744226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-04DOI: 10.1080/00365521.2025.2594786
Ibrahim Moqbel, Mohamed Mabrouk Ghonaim, Ahmed Hussein Abdelbaset, Walaa M Moawad, Ahmed Samy Gad, Ahmed Mohamed, Shrouk Eladawi, Ashraf Abdelmonem Elsayed
Background: Perforated peptic ulcer (PPU) remains a life-threatening emergency. Laparoscopic repair is favored over open surgery, but intracorporeal suturing is demanding. Interrupted hand-tied sutures are traditional; knotless barbed sutures may simplify closure and shorten operative time.
Objectives: To evaluate the efficacy and safety of knotless barbed versus interrupted sutures in laparoscopic PPU repair.
Methods: PubMed, Scopus, the Cochrane Library, Web of Science and Google Scholar were searched until 22 July 2025. Eligible comparative studies included adults undergoing laparoscopic gastroduodenal PPU repair using continuous knotless barbed sutures ± omental patch versus interrupted absorbable sutures ± omental patch. Outcomes were operative time, postoperative complications, leak, hospital stay, perforation size and wound complications. Random-effects models yielded mean differences (MDs) or risk ratios (RRs) with 95% confidence intervals (CIs) and heterogeneity (I2).
Results: Four retrospective cohorts (n = 575; 192 barbed, 383 interrupted) met criteria. Barbed sutures reduced operative time (MD -25.49 min; 95% CI -40.35 to -10.62; p = 0.0008; I2 = 43%). No differences were observed for postoperative complications (RR 0.91; 95% CI 0.54-1.53; p = 0.72; I2 = 2%), leak (RR 0.53; 95% CI 0.14-2.04; p = 0.35; I2 = 0%), hospital stay (MD -0.73 days; 95% CI -2.85 to 1.39; p = 0.50; I2 = 0%), perforation size (MD -0.06 cm; 95% CI -0.17 to 0.05; p = 0.26; I2 = 0%) or wound complications (RR 0.99; 95% CI 0.28-3.47; p = 0.99; I2 = 0%).
Conclusions: In laparoscopic PPU repair, knotless barbed sutures improve operative efficiency without increasing adverse events. Given the small, retrospective evidence base and low certainty, randomized trials with standardized techniques are warranted.
Prospero number: CRD420251119990.
Clinical trial number: Not applicable.
背景:穿孔性消化性溃疡(PPU)仍然是危及生命的急症。腹腔镜修复优于开放手术,但需要进行体内缝合。中断的手工缝合是传统的;无结倒钩缝合可简化缝合,缩短手术时间。目的:评价无结倒钩缝合与间断缝合在腹腔镜下PPU修复中的疗效和安全性。方法:检索PubMed、Scopus、Cochrane Library、Web of Science和谷歌Scholar,检索截止日期为2025年7月22日。符合条件的比较研究包括接受腹腔镜胃十二指肠PPU修复的成人,使用连续无结倒钩缝线±网膜贴片与中断可吸收缝线±网膜贴片。结果为手术时间、术后并发症、泄漏、住院时间、穿孔大小和伤口并发症。随机效应模型产生95%置信区间(ci)和异质性(I2)的平均差异(MDs)或风险比(rr)。结果:4个回顾性队列(n = 575,倒刺组192,中断组383)符合标准。有刺缝线缩短手术时间(MD -25.49 min; 95% CI -40.35 ~ -10.62; p = 0.0008; I2 = 43%)。术后并发症(RR 0.91; 95% CI 0.54-1.53; p = 0.72; I2 = 2%)、渗漏(RR 0.53; 95% CI 0.14-2.04; p = 0.35; I2 = 0%)、住院时间(MD -0.73天;95% CI -2.85 - 1.39; p = 0.50; I2 = 0%)、穿孔大小(MD -0.06 cm; 95% CI -0.17 - 0.05; p = 0.26; I2 = 0%)或伤口并发症(RR 0.99; 95% CI 0.28-3.47; p = 0.99; I2 = 0%)均无差异。结论:在腹腔镜PPU修复中,无结倒钩缝线可提高手术效率,且不增加不良事件。考虑到证据基础小、回顾性和低确定性,采用标准化技术的随机试验是有必要的。普洛斯彼罗号码:CRD420251119990。临床试验号:不适用。
{"title":"Laparoscopic repair of perforated peptic ulcer: a systematic review and meta-analysis comparing interrupted sutures versus knotless barbed sutures.","authors":"Ibrahim Moqbel, Mohamed Mabrouk Ghonaim, Ahmed Hussein Abdelbaset, Walaa M Moawad, Ahmed Samy Gad, Ahmed Mohamed, Shrouk Eladawi, Ashraf Abdelmonem Elsayed","doi":"10.1080/00365521.2025.2594786","DOIUrl":"10.1080/00365521.2025.2594786","url":null,"abstract":"<p><strong>Background: </strong>Perforated peptic ulcer (PPU) remains a life-threatening emergency. Laparoscopic repair is favored over open surgery, but intracorporeal suturing is demanding. Interrupted hand-tied sutures are traditional; knotless barbed sutures may simplify closure and shorten operative time.</p><p><strong>Objectives: </strong>To evaluate the efficacy and safety of knotless barbed versus interrupted sutures in laparoscopic PPU repair.</p><p><strong>Methods: </strong>PubMed, Scopus, the Cochrane Library, Web of Science and Google Scholar were searched until 22 July 2025. Eligible comparative studies included adults undergoing laparoscopic gastroduodenal PPU repair using continuous knotless barbed sutures ± omental patch versus interrupted absorbable sutures ± omental patch. Outcomes were operative time, postoperative complications, leak, hospital stay, perforation size and wound complications. Random-effects models yielded mean differences (MDs) or risk ratios (RRs) with 95% confidence intervals (CIs) and heterogeneity (<i>I</i><sup>2</sup>).</p><p><strong>Results: </strong>Four retrospective cohorts (<i>n</i> = 575; 192 barbed, 383 interrupted) met criteria. Barbed sutures reduced operative time (MD -25.49 min; 95% CI -40.35 to -10.62; <i>p</i> = 0.0008; <i>I</i><sup>2</sup> = 43%). No differences were observed for postoperative complications (RR 0.91; 95% CI 0.54-1.53; <i>p</i> = 0.72; <i>I</i><sup>2</sup> = 2%), leak (RR 0.53; 95% CI 0.14-2.04; <i>p</i> = 0.35; <i>I</i><sup>2</sup> = 0%), hospital stay (MD -0.73 days; 95% CI -2.85 to 1.39; <i>p</i> = 0.50; <i>I</i><sup>2</sup> = 0%), perforation size (MD -0.06 cm; 95% CI -0.17 to 0.05; <i>p</i> = 0.26; <i>I</i><sup>2</sup> = 0%) or wound complications (RR 0.99; 95% CI 0.28-3.47; <i>p</i> = 0.99; <i>I</i><sup>2</sup> = 0%).</p><p><strong>Conclusions: </strong>In laparoscopic PPU repair, knotless barbed sutures improve operative efficiency without increasing adverse events. Given the small, retrospective evidence base and low certainty, randomized trials with standardized techniques are warranted.</p><p><strong>Prospero number: </strong>CRD420251119990.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"73-83"},"PeriodicalIF":1.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145669573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-30DOI: 10.1080/00365521.2025.2594783
Zeli Yin, QiuXiang Wang, Zhe Xu, Kun Guo, Liming Wang
Background and objective: Cancer-associated fibroblasts (CAFs) promote hepatocellular carcinoma (HCC) progression. Identifying their cellular origin and molecular determinants may help to inform molecular targeted therapy for HCC. Identifying the tissue distribution of CAFs in HCC to indirectly reflect their cellular origin may provide a histological basis for further exploration of their cellular origin and molecular determinants.
Methods and results: The tissue distribution of CAFs in 57 HCC tissues was determined by immunohistochemical staining of α-SMA, and α-SMA-positive CAFs were found to be widely located along the capillary network. Immunofluorescent double staining was used to examine the co-expression of CD31 in α-SMA-positive CAFs to identify whether the endothelial-to-mesenchymal transition (EndoMT) is involved in the origin, and obvious colocalization was observed. Visium and Visium HD spatial transcriptomics further revealed endothelial cells (ECs) exhibited remarkable co-expression of CAF-specific marker genes and revealed inferred developmental trajectories to CAFs; molecular determinants, including TIMP1, IGFBP7, THBS2, CD74, COL4A1, COL4A2, AEBP1, S100A6, KCTD12, CALD1, IGHG1, SERPINE1, MCL1, MGP, GSTP1, TAGLN, THBS1, and CTGF, were positively correlated with the spatial developmental trajectories of ECs to CAFs; and CTGF exhibited extensive interactions with other common positively correlated molecular determinants and was a highly connected node in the interaction network.
Conclusion: ECs that undergo EndoMT may be one of the potential cellular and mechanical origins of CAFs in HCC, and the development of EndoMT may be associated with CTGF.
{"title":"Identification of cancer-associated fibroblasts and analysis of the association of origin with endothelial-to-mesenchymal transition in hepatocellular carcinoma.","authors":"Zeli Yin, QiuXiang Wang, Zhe Xu, Kun Guo, Liming Wang","doi":"10.1080/00365521.2025.2594783","DOIUrl":"10.1080/00365521.2025.2594783","url":null,"abstract":"<p><strong>Background and objective: </strong>Cancer-associated fibroblasts (CAFs) promote hepatocellular carcinoma (HCC) progression. Identifying their cellular origin and molecular determinants may help to inform molecular targeted therapy for HCC. Identifying the tissue distribution of CAFs in HCC to indirectly reflect their cellular origin may provide a histological basis for further exploration of their cellular origin and molecular determinants.</p><p><strong>Methods and results: </strong>The tissue distribution of CAFs in 57 HCC tissues was determined by immunohistochemical staining of α-SMA, and α-SMA-positive CAFs were found to be widely located along the capillary network. Immunofluorescent double staining was used to examine the co-expression of CD31 in α-SMA-positive CAFs to identify whether the endothelial-to-mesenchymal transition (EndoMT) is involved in the origin, and obvious colocalization was observed. Visium and Visium HD spatial transcriptomics further revealed endothelial cells (ECs) exhibited remarkable co-expression of CAF-specific marker genes and revealed inferred developmental trajectories to CAFs; molecular determinants, including TIMP1, IGFBP7, THBS2, CD74, COL4A1, COL4A2, AEBP1, S100A6, KCTD12, CALD1, IGHG1, SERPINE1, MCL1, MGP, GSTP1, TAGLN, THBS1, and CTGF, were positively correlated with the spatial developmental trajectories of ECs to CAFs; and CTGF exhibited extensive interactions with other common positively correlated molecular determinants and was a highly connected node in the interaction network.</p><p><strong>Conclusion: </strong>ECs that undergo EndoMT may be one of the potential cellular and mechanical origins of CAFs in HCC, and the development of EndoMT may be associated with CTGF.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"143-157"},"PeriodicalIF":1.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}